Treatment of peritonitis in APD: Pharmacokinetic principles

Seminars in Dialysis

Volumn 15, Issue 6, 2002, Pages 418-421

  Manley, Harold J ^a   Bailie, George R ^b,c  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DIALYSIS FLUID;

AUTOMATION; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; HALF LIFE TIME; HUMAN; PERITONEAL DIALYSIS; PERITONITIS; REVIEW;

ANTI-BACTERIAL AGENTS; AUTOMATION; DIALYSIS SOLUTIONS; HALF-LIFE; HUMANS; PERITONEAL DIALYSIS; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; PERITONITIS;

EID: 0036835306     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-139X.2002.00103.x     Document Type: Conference Paper

References (15)

1. Keane WF, Bailie GR, Boeschoten E, Gokal R, Golper TA, Holmes CJ, Kawaguchi Y, Piraino B, Riella M, Vas S: ISPD guidelines/recommendations. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Perit Dial Int 20:396-111, 2000
2. Shemin D, Maaz D, St. Pierre D, Kahn SI, Chazan JA: Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. Am J Kidney Dis 34:14-20, 1999
3. Ronco C, Clark W: Factors affecting hemodialysis and peritoneal dialysis efficiency. Semin Dial 14:257-262, 2001
4. U.S. Renal Data System: USRDS 2000 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001
5. Gokal R: Peritoneal dialysis in the 21st century: an analysis of current problems and future developments. J Am Soc Nephrol 13:S104-S116, 2002
6. Diaz-Buxo JA, Crawford TL, Bailie GR: Peritonitis in automated peritoneal dialysis: antibiotic therapy and pharmacokinetics. Perit Dial Int 21(suppl 3): S197-S201, 2001
7. Manley HJ, Bailie GR, Frye R, Hess LD, McGoldrick MD: Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. J Am Soc Nephrol 11:1310-1316, 2000
8. Manley HJ, Bailie GR, Frye RF, McGoldrick MD: Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients. Perit Dial Int 21:378-385, 2001
9. Manley HJ, Bailie GR, Frye R, McGoldrick MD: Intermittent intravenous piperacillin pharmacokinetics in automated peritoneal dialysis patients. Perit Dial Int 20:686-693, 2000
10. Dahl NV, Foote EF, Searson KM, Fein JL, Kapoian T, Steward CA, Sherman RA: Pharmacokinetics of intraperitoneal fluconazole during continuous cycling peritoneal dialysis. Ann Pharmacother 32:1284-1289, 1995
11. Manley HJ, Bailie GR, Asher RD, Eisele G, Frye RF: Pharmacokinetics of intermittent intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 19:65-70, 1999
12. Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC: Tobramycin kinetics during continuous ambulatory peritoneal dialysis. Clin Pharmacol Ther 34:110-116, 1983
13. Morse GD, Farolino DF, Apicella MA, Walshe JJ: Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis. Antimicrob Agent Chemother 31:173-177, 1987
14. Johnson CA, Halstenson CE, Kelloway JS, Shapiro BE, Zimmerman SW, Torelli A, Faulkner R, Dutta A, Haynes J, Greene DS. Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther 51:32-41, 1992
15. Debruyne D, Ryckelynck JP, de Moulin M, Lagny BH, Levaltier B, Bugot Mc: Pharmacokinetics of fluconazole in patients undergoing continuous ambulatory peritoneal dialysis. Clin Pharmacokinet 18:491-498, 1990